Cargando…
Cancer immunotherapy: Benefit and harm?
In this article, evidence is reviewed suggesting that the outcome of cancer immunotherapy depends on pre-treatment immune parameters of a patient. The results described in the article show that immunotherapy may prolong survival in certain subgroups of cancer patients, while in other subgroups a can...
Autor principal: | Characiejus, Dainius |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3376986/ https://www.ncbi.nlm.nih.gov/pubmed/22720253 http://dx.doi.org/10.4161/onci.1.2.18183 |
Ejemplares similares
-
Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014) -
Radiation and immunotherapy: Renewed allies in the war on cancer
por: Seung, Steven K., et al.
Publicado: (2012) -
Chemokine-enhanced DNA vaccination in cancer immunotherapy
por: Igoucheva, Olga, et al.
Publicado: (2013) -
Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013) -
Cancer cell associated glycans as targets for immunotherapy
por: Vankemmelbeke, Mireille, et al.
Publicado: (2015)